Clinical Trial Update: Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002) [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for MK-8504 in ART-naïve HIV-1 infected participants; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• MK-8504 (MK-8504)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 1 | Status: COMPLETED | Results posted: 2019-07-15